Search Results
Your search for By Matthew Stenger matches 7295 pages
Showing 5001 - 5050ASCO Clinical Practice Guideline Update: Integration of Palliative Care Into Standard Oncology Care
As reported by Betty R. Ferrell, PhD, of the City of Hope Medical Center, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline update on the integration of palliative care into standard oncology care. This update of a 2012 ASCO provisional clinical...
Diagnostic Laparoscopy May Predict Result of Primary Cytoreductive Surgery in Suspected Advanced Ovarian Cancer
In a Dutch trial reported in the Journal of Clinical Oncology, Rutten et al found that initial diagnostic laparoscopy can prevent futile primary cytoreductive surgery in patients with suspected advanced-stage ovarian cancer. Study Details In the trial, 201 women who were qualified for primary...
No Improvement in Event-Free Survival Reported With More Extensive or Serial Resections in Wild-Type GIST
Findings from the National Institutes of Health Pediatric and Wildtype Gastrointestinal Stromal Tumors (GISTs) Clinic, reported in the Journal of Clinical Oncology by Weldon et al, indicate that more extensive or serial resections are not associated with improvement in event-free survival in...
Benefit of Early Integrated Palliative Care in Patients With Newly Diagnosed Incurable Cancer
In a study reported in the Journal of Clinical Oncology, Temel et al found that early integration of palliative care resulted in better quality of life and reduced depression in patients with newly diagnosed incurable lung or noncolorectal gastrointestinal cancer. Outcomes differed by cancer type. ...
Germline Cancer Susceptibility Mutations in Early-Onset Colorectal Cancer
In a study reported in JAMA Oncology, Pearlman et al found that 16% of patients with early-onset colorectal cancer had germline cancer susceptibility mutations, with a wide array of such mutations being identified. The study involved 450 patients diagnosed with colorectal cancer at age < 50...
Comparison of Scales for Assessing Cisplatin-Related Ototoxicity in Children
In a study reported in the Journal of Clinical Oncology, Knight et al of the Children’s Oncology Group found that the Society for Industrial and Organizational Psychology Ototoxicity (SIOP) scale may be more sensitive than other classification systems in detecting ototoxicity in children...
Customer Response to Personal Genomic Testing for Cancer Risk
In a study reported in the Journal of Clinical Oncology, Gray et al found that most people receiving cancer-related data through direct-to-consumer personal genomic testing tended not to change health or screening behaviors when an elevated risk was identified. The study involved baseline and...
Vascular-Targeted Photodynamic Therapy Shows Promise in Low-Risk Prostate Cancer
In a European phase III trial reported in The Lancet Oncology, Azzouzi et al found that padeliporfin vascular-targeted photodynamic therapy was associated with a reduced rate of disease progression vs active surveillance in men with low-risk prostate cancer. Study Details In the open-label trial, ...
Is Adding Onartuzumab to Erlotinib of Benefit in Advanced Non–Small Cell Lung Cancer?
In a phase III METLung trial reported in the Journal of Clinical Oncology, Spigel et al found that adding the MET inhibitor onartuzumab to erlotinib (Tarceva) was of no benefit in patients with MET-positive advanced non–small cell lung cancer (NSCLC) who had progressed after platinum-based...
Maintenance Olaparib in Platinum-Sensitive Recurrent Serous Ovarian Cancer With BRCA Mutation
Maintenance olaparib (Lynparza) appeared to be associated with an overall survival benefit vs placebo in women with platinum-sensitive serous ovarian cancer and BRCA1 and BRCA2 mutations, according to an updated analysis of a phase II trial reported in The Lancet Oncology by Jonathan A. Ledermann,...
Study Identifies Factors in Clonal Evolution of Chemotherapy-Resistant Urothelial Carcinoma
In a study reported in Nature Genetics, Bishoy M. Faltas, MD, of Weill Cornell Medicine, and colleagues identified factors in the clonal evolution of chemotherapy-resistant urothelial carcinoma.1 As stated by the investigators: “Chemotherapy-resistant urothelial carcinoma has no uniformly curative...
Addition of Palbociclib to Letrozole in Previously Untreated Advanced Estrogen Receptor–Positive, HER2-Negative Breast Cancer
In the phase III PALOMA-2 trial reported in The New England Journal of Medicine, Richard S. Finn, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues found that the addition of palbociclib (Ibrance) to letrozole significantly improved...
Improved Survival With Higher Tumor-Infiltrating Lymphocyte Values in Advanced HER2-Positive Breast Cancer
In a retrospective analysis of the phase III CLEOPATRA trial reported in The Lancet Oncology, Luen et al found that higher baseline tumor-infiltrating lymphocyte levels were associated with improved overall survival among patients with advanced HER2-positive breast cancer receiving trastuzumab...
Atezolizumab Shows Activity in First-Line Treatment of Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma
In a phase II trial reported in The Lancet, Balar et al found that first-line atezolizumab (Tecentriq) produced durable responses in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. In the study, 119 patients from 47 sites in North America and Europe who were ...
Atezolizumab Improves Survival vs Docetaxel in Previously Treated Non–Small Cell Lung Cancer
In the phase III OAK trial reported in The Lancet by Rittmeyer et al, treatment with the anti–programmed cell death ligand 1 (PD-L1) antibody atezolizumab (Tecentriq) improved overall survival vs docetaxel in previously treated non–small cell lung cancer (NSCLC). Results of the trial...
T-Cell Transfer Therapy Targets Mutant KRAS in Metastatic Colorectal Cancer
In a case report in The New England Journal of Medicine, Tran et al at the National Cancer Institute describe response to adoptive transfer of ex vivo expanded tumor-infiltrating lymphocytes containing T cells targeting personalized cancer neoepitopes in a patient with lung metastases from...
ASCO Makes No Changes to 2014 Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
As reported in the Journal of Clinical Oncology by Gary H. Lyman, MD, of Fred Hutchinson Cancer Research Center, and colleagues, an ASCO clinical practice guideline update panel made no changes to the 2014 recommendations for sentinel lymph node biopsy in women with early-stage breast cancer. The...
Study Finds Regorafenib Improves Survival in Patients With Hepatocelluar Carcinoma Progressing on Sorafenib
Regorafenib (Stivarga) improved overall survival vs placebo in patients with hepatocellular carcinoma who had experienced disease progression on sorafenib (Nexavar) treatment, according to the phase III RESORCE trial reported by Bruix et al in The Lancet. Study Details In this double-blind trial, ...
Addition of Adjuvant Chemotherapy to Chemoradiotherapy Achieves Best Survival Results in Locally Advanced Nasopharyngeal Carcinoma
In an individual patient-data meta-analysis reported in the Journal of Clinical Oncology, Ribassin-Majed et al in the Meta-analysis of Chemotherapy in Nasopharyngeal Collaborative Group found that the addition of adjuvant chemotherapy to chemoradiotherapy was associated with the greatest overall...
First-in-Class Rovalpituzumab Tesirine Active in Recurrent Small Cell Lung Cancer
In a phase I study reported in The Lancet Oncology, Rudin et al found that rovalpituzumab tesirine, a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), produced responses in patients with recurrent small cell lung cancer (SCLC). DLL3 is a target identified in...
ASCO Clinical Practice Guideline on Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers
As reported in the Journal of Clinical Oncology by Saro H. Armenian, DO, MPH, of City of Hope, and colleagues, ASCO has released a clinical practice guideline on prevention and monitoring of cardiac dysfunction in survivors of adult cancers. Recommendations were developed by an expert panel using a ...
Promising Activity Seen With First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small Cell Lung Cancer
As reported in The Lancet Oncology by Hellman et al, the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed promising activity as first-line treatment in patients in the non–small cell lung cancer (NSCLC) cohort of the phase I CheckMate 012 study. Study Details In the...
Osimertinib Improves Progression-Free Survival vs Platinum/Pemetrexed in EGFR T790M–Positive NSCLC
In the phase III AURA3 trial reported in The New England Journal of Medicineby Mok et al, osimertinib (Tagrisso) significantly improved progression-free survival (PFS) vs platinum/pemetrexed (Alimta) among patients with epidermal growth factor receptor (EGFR) T790M–positive non–small...
Rucaparib Appears Effective in Relapsed Platinum-Sensitive High-Grade Ovarian Carcinoma
In part 1 of the phase II ARIEL2 trial reported in The Lancet Oncology, Swisher et al found that the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib was associated with prolonged progression-free survival among patients with relapsed platinum-sensitive high-grade ovarian carcinoma who had...
Phase III Trial Shows Improved Progression-Free Survival With Fulvestrant vs Anastrozole in Hormone Receptor–Positive Advanced Breast Cancer
In the international phase III FALCON trial reported in The Lancet, Robertson et al found that progression-free survival was improved with intramuscular fulvestrant (Faslodex) vs oral anastrozole in endocrine therapy–naive women with hormone receptor–positive locally advanced or...
Sodium Thiosulfate Seems to Protect Against Cisplatin-Related Hearing Loss in Children With Cancer
The antioxidant sodium thiosulfate provided protection against cisplatin-related hearing loss in children with cancer, according to a phase III trial reported by Freyer et al in The Lancet Oncology. The open-label trial included 104 assessable patients (aged 1 to 18 years) from 38 Children’s ...
Concerns About Safety of Generic Oncology Drugs Made in Developing Countries
In an article in The Lancet Oncology, Y. Tony Yang, ScD, of George Mason University, Charles L. Bennett, MD, PhD, MPP, of the University of South Carolina and colleagues from the United States, Europe, and Japan examined clinical, policy, safety, and regulatory considerations for generic oncology...
Daratumumab in Previously Treated Multiple Myeloma
On November 21, 2016, daratumumab (Darzalex) was approved for use in combination with lenalidomide (Revlimid) and dexamethasone or with bortezomib (Velcade) and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.1,2 The drug was initially ...
No Progression-Free Survival Difference With Temozolomide vs Radiotherapy in High-Risk Low-Grade Glioma
In a phase III intergroup trial reported in The Lancet Oncology, Brigitta G. Baumert, MD, of the European Organisation for Research and Treatment of Cancer (EORTC), Brussels, and colleagues found no progression-free survival difference between temozolomide chemotherapy and radiotherapy alone in...
Successful Retreatment With Cisplatin-Based Therapy Reported in Men Relapsing After Adjuvant Carboplatin for Stage I Seminoma
In an analysis reported in the Journal of Clinical Oncology, Fischer et al found that men with clinical stage I seminoma who relapsed after adjuvant carboplatin could be successfully re-treated with cisplatin-based chemotherapy. Study Details The analysis included data from 185 patients who...
No Significant Benefit of Perindopril or Bisoprolol in Reducing Trastuzumab-Associated Cardiac Remodeling in HER2-Positive Breast Cancer
Use of the angiotensin-converting enzyme inhibitor perindopril or the beta-blocker bisoprolol did not reduce the risk of trastuzumab (Herceptin)-related cardiac remodeling in women with HER2-positive early breast cancer, according to a Canadian trial reported by Pituskin et al in the Journal of...
Equivalent Response Rates With Trastuzumab or Trastuzumab Biosimilar Plus Taxane in HER2-Positive Metastatic Breast Cancer
In part 1 of a phase III equivalence trial reported in JAMA, Rugo et al found that treatment with trastuzumab (Herceptin) or a proposed trastuzumab biosimilar in combination with a taxane produced similar overall response rates in patients with previously untreated metastatic HER2-positive breast...
Study Finds No Predictive Value of ERCC1 Marker for Outcomes With Nonplatinum vs Platinum Therapies in NSCLC
In the UK phase III ERCC1 trial reported in the Journal of Clinical Oncology, Lee et al found that presence of the excision repair cross complementing group 1 (ERCC1) biomarker did not predict better outcome with nonplatinum therapy in patients with non–small cell lung cancer (NSCLC). Study...
ASCO Endorses ASTRO Guideline on Radiation Therapy for Glioblastoma
As reported by Erik P. Sulman, MD, PhD, of MD Anderson Cancer Center, and colleagues in the Journal of Clinical Oncology, ASCO has endorsed the 2016 American Society for Radiation Oncology (ASTRO) evidence-based guideline on radiation therapy for glioblastoma. The endorsement was based on review of ...
Does Androgen-Deprivation Therapy Increase the Risk for Dementia in Patients With Prostate Cancer?
In a UK population–based study reported in the Journal of Clinical Oncology, Khosrow-Khavar et al found no significant association between the use of androgen-deprivation therapy and the risk for dementia in patients with prostate cancer. The study involved a cohort of 30,903 men with newly...
Activating NOTCH1 Mutations Identify Poor-Prognostic Subgroup With Adenoid Cystic Carcinoma
In a study reported in the Journal of Clinical Oncology, Ferrarotto et al found that the presence of activating NOTCH1 mutations defined a subgroup of patients with adenoid cystic carcinomas with an aggressive phenotype. Frequency of Mutations The study included genotyping of 102 adenoid cystic...
Assessment of Therapeutic Response by Intrinsic Subtype for HER2-Positive Breast Tumors
In an analysis of outcomes in the North Central Cancer Treatment Group/Alliance N9831 trial reported in the Journal of the National Cancer Institute, Perez et al found that patients with tumors scored as HER2-enriched or luminal subtype derived a recurrence-free survival benefit from the addition...
Increased Morbidity and Mortality in HCT Survivors vs Other Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Chow et al found that hematopoietic cell transplantation survivors had higher rates of morbidity and mortality compared with a matched population of patients with cancer not undergoing hematopoietic cell transplantation. The study involved...
High Frequency and Poor Outcome of Philadelphia Chromosome–Like ALL Reported in Adults
In a study reported in the Journal of Clinical Oncology, Roberts et al found a high frequency of Philadelphia chromosome (Ph)–like acute lymphoblastic leukemia (ALL) in adults with B-cell ALL and poorer outcome with conventional therapy in these patients. Frequency of Disease The frequency...
Association of Extent of Surgeon-Assessed Resection on Outcome in High-Risk Neuroblastoma
In an analysis of patients with high-risk neuroblastoma from the Children’s Oncology Group A3973 study reported in the Journal of Clinical Oncology, von Allmen et al found that surgeon-assessed resection of at least 90% was associated with improved event-free survival and a reduced cumulative ...
Obesity/Overweight and Lower Activity Level May Increase Risk of Taxane-Induced Neuropathy in Women With Invasive Breast Cancer
Greenlee et al found that obesity, overweight, and low levels of moderate-to-vigorous physical activity were associated with an increased risk of taxane-related peripheral neuropathy in women with invasive breast cancer, according to a study reported in the Journal of the National Cancer Institute. ...
High-Dose Chemotherapy and Autologous PBSCT for Relapsed Metastatic Germ Cell Tumors
In a retrospective analysis reported in the Journal of Clinical Oncology, Adra et al found that good survival outcomes were achieved with the use of high-dose chemotherapy and peripheral blood stem cell transplantation (PBSCT) in second-, third-, or later-line treatment of patients with relapsed...
Projected Financial Burden of Targeted Therapies for Chronic Lymphocytic Leukemia
In an analysis reported in the Journal of Clinical Oncology, Chen et al predicted that an increase in the number of patients living with chronic lymphocytic leukemia (CLL) due to improved treatment with oral targeted therapies will be accompanied by a markedly increased overall cost to patients and ...
Can Mindfulness-Based Cognitive Therapy Reduce Distress in Patients With Advanced Prostate Cancer?
Chambers et al found that a mindfulness-based cognitive therapy intervention did not improve measures of distress or anxiety vs minimally enhanced usual care among men with advanced prostate cancer, according to an Australian study reported in the Journal of Clinical Oncology. In the study, 189...
Study Finds Serum DNA Methylation an Early Marker of Response and Survival in Metastatic Breast Cancer
In the Translational Breast Cancer Research Consortium (TBCRC) 005 prospective biomarker study, reported in the Journal of Clinical Oncology by Visvanathan et al, a cumulative methylation index was found to be predictive of progression-free survival, overall survival, and disease status at first...
Study Shows Modestly Reduced Breast Cancer Recurrence Risk With Increased Protein Intake Independent of Tumor Insulin Receptor Status
In an analysis in the Nurses’ Health Study population reported in the Journal of Clinical Oncology, Holmes et al found modest reductions in the risk for distant recurrence of breast cancer with greater protein intake. No associations with intake of essential amino acids, branched-chain amino...
Link Between Previous Treatment for Depression and Increased Risk of Receiving Nonguideline Treatment in Early-Stage Breast Cancer
Women with early-stage breast cancer previously treated for depression were more likely to receive nonguideline treatment for breast cancer, “probably contributing to poorer overall and cancer-specific survival,” according to a nationwide Danish cohort study reported in the Journal of...
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From ASCT in NPM1-Mutant AML
In an analysis of a French trial reported in the Journal of Clinical Oncology, Balsat et al found that postinduction minimal residual disease was predictive of outcome and benefit from allogeneic stem cell transplantation (ASCT) in patients with NPM1-mutant acute myeloid leukemia (AML). The study...
Safety Profile of Nivolumab Monotherapy in Advanced Melanoma
As reported in the Journal of Clinical Oncology, Weber et al performed a pooled analysis of the safety profile of nivolumab (Opdivo) monotherapy in advanced melanoma, including a focus on potential immune-related (select) adverse events. The analysis pooled safety data from 576 patients receiving...
Factors Predictive of Outcomes With Dabrafenib/Trametinib in Metastatic BRAF-Mutant Melanoma
Long et al identified factors predictive of progression-free and overall survival with combined dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF V600E–mutant or BRAF V600K–mutant metastatic melanoma, according to a pooled individual data analysis reported in The...
